Blood neurofilament light chain as a biomarker for monitoring and predicting paclitaxel-induced peripheral neuropathy in patients with gynecological cancers
ObjectiveWe aimed to evaluate the potential of serum neurofilament light chain (sNfL) and serum brain-derived neurotrophic factor (sBDNF) as reliable biomarkers for paclitaxel-induced peripheral neuropathy (PIPN).MethodsForty-eight patients with gynecologic cancer scheduled to undergo six cycles of...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.942960/full |
| _version_ | 1827823181626343424 |
|---|---|
| author | Su-Hyun Kim Ki Hoon Kim Jae-Won Hyun Ji Hyun Kim Sang-Soo Seo Ho Jin Kim Sang-Yoon Park Myong Cheol Lim Myong Cheol Lim Myong Cheol Lim Myong Cheol Lim Myong Cheol Lim |
| author_facet | Su-Hyun Kim Ki Hoon Kim Jae-Won Hyun Ji Hyun Kim Sang-Soo Seo Ho Jin Kim Sang-Yoon Park Myong Cheol Lim Myong Cheol Lim Myong Cheol Lim Myong Cheol Lim Myong Cheol Lim |
| author_sort | Su-Hyun Kim |
| collection | DOAJ |
| description | ObjectiveWe aimed to evaluate the potential of serum neurofilament light chain (sNfL) and serum brain-derived neurotrophic factor (sBDNF) as reliable biomarkers for paclitaxel-induced peripheral neuropathy (PIPN).MethodsForty-eight patients with gynecologic cancer scheduled to undergo six cycles of paclitaxel-based chemotherapy at the National Cancer Center of Korea between September 2020 and January 2022 were prospectively assessed during and after chemotherapy.ResultsAt the end of the chemotherapy, 12 (25%) patients were classified as having grade 3 PIPN according to the National Cancer Institute-Common Toxicity Criteria. The sNfL levels increased during paclitaxel treatment in all patients. After two, four, and six cycles, patients with grade 3 PIPN exhibited higher mean sNfL levels than those in the 0–2 grade range (p = 0.004, p = 001, and p < 0.001, respectively). For sNfL levels ≥ 124 pg/mL, after two cycles of chemotherapy, the sensitivity and specificity for predicting grade 3 PIPN at the end of treatment were 80% and 79%, respectively. Over the course of paclitaxel-based treatment, sBDNF levels continued to decrease regardless of the severity of PIPN. At the end of treatment and six months after chemotherapy, patients with grade 3 PIPN had lower sBDNF levels than those within the 0–2 grade range (p =0.037 and 0.02, respectively), and the patients in the latter group had better clinical symptoms six months after the end of treatment.ConclusionsThe sNfL levels during paclitaxel-based chemotherapy reflect ongoing neuroaxonal injury and serve as reliable biomarkers of PIPN severity. The sNfL levels during early treatment with paclitaxel might be prognostic indicators for PIPN progression. Low sBDNF levels 6 months after chemotherapy might adversely affect PIPN recovery. |
| first_indexed | 2024-03-12T02:08:30Z |
| format | Article |
| id | doaj.art-b8006aa92d534fdb93700bbb74395280 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-12T02:08:30Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-b8006aa92d534fdb93700bbb743952802023-09-06T19:49:49ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-08-011210.3389/fonc.2022.942960942960Blood neurofilament light chain as a biomarker for monitoring and predicting paclitaxel-induced peripheral neuropathy in patients with gynecological cancersSu-Hyun Kim0Ki Hoon Kim1Jae-Won Hyun2Ji Hyun Kim3Sang-Soo Seo4Ho Jin Kim5Sang-Yoon Park6Myong Cheol Lim7Myong Cheol Lim8Myong Cheol Lim9Myong Cheol Lim10Myong Cheol Lim11Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, South KoreaDepartment of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, South KoreaDepartment of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, South KoreaCenter for Gynecologic Cancer, National Cancer Center, Goyang, South KoreaCenter for Gynecologic Cancer, National Cancer Center, Goyang, South KoreaDepartment of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, South KoreaCenter for Gynecologic Cancer, National Cancer Center, Goyang, South KoreaCenter for Gynecologic Cancer, National Cancer Center, Goyang, South KoreaCenter for Clinical Trial, Hospital, National Cancer Center, Goyang, South KoreaDepartment of Cancer Control and Population Health, National Cancer Center Graduate School of Cancer Science and Policy, Goyang, South KoreaRare and Pediatric Cancer Branch and Immuno-oncology Branch, Division of Rare and Refractory Cancer, Research Institute, National Cancer Center, Goyang, South KoreaDepartment of Cancer Control and Policy, National Cancer Center, Goyang, South KoreaObjectiveWe aimed to evaluate the potential of serum neurofilament light chain (sNfL) and serum brain-derived neurotrophic factor (sBDNF) as reliable biomarkers for paclitaxel-induced peripheral neuropathy (PIPN).MethodsForty-eight patients with gynecologic cancer scheduled to undergo six cycles of paclitaxel-based chemotherapy at the National Cancer Center of Korea between September 2020 and January 2022 were prospectively assessed during and after chemotherapy.ResultsAt the end of the chemotherapy, 12 (25%) patients were classified as having grade 3 PIPN according to the National Cancer Institute-Common Toxicity Criteria. The sNfL levels increased during paclitaxel treatment in all patients. After two, four, and six cycles, patients with grade 3 PIPN exhibited higher mean sNfL levels than those in the 0–2 grade range (p = 0.004, p = 001, and p < 0.001, respectively). For sNfL levels ≥ 124 pg/mL, after two cycles of chemotherapy, the sensitivity and specificity for predicting grade 3 PIPN at the end of treatment were 80% and 79%, respectively. Over the course of paclitaxel-based treatment, sBDNF levels continued to decrease regardless of the severity of PIPN. At the end of treatment and six months after chemotherapy, patients with grade 3 PIPN had lower sBDNF levels than those within the 0–2 grade range (p =0.037 and 0.02, respectively), and the patients in the latter group had better clinical symptoms six months after the end of treatment.ConclusionsThe sNfL levels during paclitaxel-based chemotherapy reflect ongoing neuroaxonal injury and serve as reliable biomarkers of PIPN severity. The sNfL levels during early treatment with paclitaxel might be prognostic indicators for PIPN progression. Low sBDNF levels 6 months after chemotherapy might adversely affect PIPN recovery.https://www.frontiersin.org/articles/10.3389/fonc.2022.942960/fullpaclitaxelneuropathyneurofilament light (NfL)gynecological cancerchemotherapy induced peripheral neuropathy |
| spellingShingle | Su-Hyun Kim Ki Hoon Kim Jae-Won Hyun Ji Hyun Kim Sang-Soo Seo Ho Jin Kim Sang-Yoon Park Myong Cheol Lim Myong Cheol Lim Myong Cheol Lim Myong Cheol Lim Myong Cheol Lim Blood neurofilament light chain as a biomarker for monitoring and predicting paclitaxel-induced peripheral neuropathy in patients with gynecological cancers Frontiers in Oncology paclitaxel neuropathy neurofilament light (NfL) gynecological cancer chemotherapy induced peripheral neuropathy |
| title | Blood neurofilament light chain as a biomarker for monitoring and predicting paclitaxel-induced peripheral neuropathy in patients with gynecological cancers |
| title_full | Blood neurofilament light chain as a biomarker for monitoring and predicting paclitaxel-induced peripheral neuropathy in patients with gynecological cancers |
| title_fullStr | Blood neurofilament light chain as a biomarker for monitoring and predicting paclitaxel-induced peripheral neuropathy in patients with gynecological cancers |
| title_full_unstemmed | Blood neurofilament light chain as a biomarker for monitoring and predicting paclitaxel-induced peripheral neuropathy in patients with gynecological cancers |
| title_short | Blood neurofilament light chain as a biomarker for monitoring and predicting paclitaxel-induced peripheral neuropathy in patients with gynecological cancers |
| title_sort | blood neurofilament light chain as a biomarker for monitoring and predicting paclitaxel induced peripheral neuropathy in patients with gynecological cancers |
| topic | paclitaxel neuropathy neurofilament light (NfL) gynecological cancer chemotherapy induced peripheral neuropathy |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.942960/full |
| work_keys_str_mv | AT suhyunkim bloodneurofilamentlightchainasabiomarkerformonitoringandpredictingpaclitaxelinducedperipheralneuropathyinpatientswithgynecologicalcancers AT kihoonkim bloodneurofilamentlightchainasabiomarkerformonitoringandpredictingpaclitaxelinducedperipheralneuropathyinpatientswithgynecologicalcancers AT jaewonhyun bloodneurofilamentlightchainasabiomarkerformonitoringandpredictingpaclitaxelinducedperipheralneuropathyinpatientswithgynecologicalcancers AT jihyunkim bloodneurofilamentlightchainasabiomarkerformonitoringandpredictingpaclitaxelinducedperipheralneuropathyinpatientswithgynecologicalcancers AT sangsooseo bloodneurofilamentlightchainasabiomarkerformonitoringandpredictingpaclitaxelinducedperipheralneuropathyinpatientswithgynecologicalcancers AT hojinkim bloodneurofilamentlightchainasabiomarkerformonitoringandpredictingpaclitaxelinducedperipheralneuropathyinpatientswithgynecologicalcancers AT sangyoonpark bloodneurofilamentlightchainasabiomarkerformonitoringandpredictingpaclitaxelinducedperipheralneuropathyinpatientswithgynecologicalcancers AT myongcheollim bloodneurofilamentlightchainasabiomarkerformonitoringandpredictingpaclitaxelinducedperipheralneuropathyinpatientswithgynecologicalcancers AT myongcheollim bloodneurofilamentlightchainasabiomarkerformonitoringandpredictingpaclitaxelinducedperipheralneuropathyinpatientswithgynecologicalcancers AT myongcheollim bloodneurofilamentlightchainasabiomarkerformonitoringandpredictingpaclitaxelinducedperipheralneuropathyinpatientswithgynecologicalcancers AT myongcheollim bloodneurofilamentlightchainasabiomarkerformonitoringandpredictingpaclitaxelinducedperipheralneuropathyinpatientswithgynecologicalcancers AT myongcheollim bloodneurofilamentlightchainasabiomarkerformonitoringandpredictingpaclitaxelinducedperipheralneuropathyinpatientswithgynecologicalcancers |